Formulation Brief & Sample Request Guide for Acid Exfoliation Technology

Key Technical Parameters #

Most brand founders we talk to for the first time arrive with a mood board, a competitor product they want to beat, and no idea what we actually need from them to start working. That gap costs weeks. The acid exfoliation category compounds this because pH, free acid fraction, and market destination aren’t details you can fill in later — they determine the formula from day one. This guide is written for the brand owner who’s ready to develop but hasn’t engaged an OEM before, covering exactly what to put in a brief, what to expect back, and where the process typically breaks down. Our acid-exfoliation-technology platform covers everything from glycolic toners at pH 3.2 to professional-grade AHA/BHA blends, and the intake process is the same regardless of complexity.

What Goes Into a Brief That Actually Works #

When a brand partner sends us a brief, the first thing we do is check whether it answers four questions: what market is this for, what claim are you making, what does the consumer expect to feel, and are there ingredients you cannot use. If any of those are missing, we send it back. Not because we’re difficult — because without those four answers, we’d be formulating into a void.

Market destination drives pH ceiling. Under EU Cosmetics Regulation 1223/2009, leave-on AHA products are restricted to 10% concentration with a minimum pH of 3.5 for consumer products. The FDA Cosmetics Guidelines don’t set a hard concentration cap, but the FDA/PCPC voluntary guideline recommends pH ≥ 3.5 for leave-on products at concentrations above 10%. If you’re targeting China, the NMPA Cosmetic Regulation operates differently again — alpha hydroxy acids require specific safety evaluation submissions above certain thresholds, and the registration timeline for new formulas adds 3–6 months to your go-to-market. We log the target market as the first field in our internal brief intake form, which we call the FI-01 Formulation Request Sheet. Everything downstream depends on it.

The claim you make determines the pH floor. A brand that wants “visibly smoother skin in 14 days” needs a free acid fraction that actually does something at the epidermal level. That typically means staying at or below pH 3.8 for glycolic-dominant formulas at 8–10% total AHA. If you want to call it a “gentle daily exfoliant” suitable for sensitive skin, we’re probably working at pH 4.5–5.0 with PHAs or mandelic acid, and the claim language shifts accordingly. We almost always push back when a brief asks for “maximum efficacy and suitable for sensitive skin” without specifying which one is the priority. Pick one. The formula will too.

Texture preference is more important than most briefs acknowledge. Clients who specify “lightweight watery essence” and then also request 2% salicylic acid create a solubility problem from the start. BHA at that concentration in a water-forward system requires either propylene glycol as a co-solvent (around 8–12% depending on other solubilizers), a hydroalcoholic base, or a different concentration. We’ll propose a solution, but we need to know upfront whether alcohol is acceptable, because some brands have clean-beauty positioning that makes hydroalcoholic bases a marketing problem regardless of the chemistry.

Ingredient exclusions matter as much as inclusions. Vegan status, fragrance-free, silicone-free, paraben-free — these aren’t just marketing constraints. They remove tools from the formulator’s kit. Preserving an aqueous acid exfoliant without parabens at pH 3.5–4.0 is solvable, but the preservation system looks different and costs more. We work through this during brief intake rather than discovering it at stability review.

One category of brief mistake we see consistently: brands submit a benchmark product and say “make us something like this.” That’s useful context, but it’s not a brief. We’ll use it as a texture and positioning reference, but the formula we develop will be designed to your regulatory market and your supply chain — not reverse-engineered from a competitor’s INCI list.

Diagnostic Table: Brief Quality vs. Project Outcome #

Below is what we’ve observed across projects over roughly three years of intake data. This isn’t a guarantee, but it reflects the pattern well enough that we now use brief completeness as an early predictor of project timeline.

The “stall” category is what everyone wants to avoid. We’ve had projects where a minimal brief got us all the way to pilot batch before the brand confirmed they were entering the EU market — at which point the 12% glycolic acid formula at pH 3.2 needed to be reformulated from the ground up. Eight weeks of stability data, gone.

MOQ, Development Fees, and the Real Cost Structure #

Sample-stage costs and production costs are two completely different conversations, and brands new to OEM development often conflate them.

For initial lab samples, we typically produce 100–200g evaluation batches per variant. No MOQ in the traditional sense — this is bench-scale work. The development fee structure we use covers formulation labor, raw material procurement, and initial physicochemical testing (pH, viscosity, appearance). For a standard acid exfoliant in the 1–3 formula variant range, development fees typically fall in the $800–$2,500 USD range depending on complexity. Encapsulated acid systems or dual-phase formats sit at the higher end because the encapsulation technology involved requires additional equipment time and raw material sourcing.

Production MOQ for acid exfoliation formats depends heavily on packaging format. Pump bottles and dropper formats generally start at 3,000 units per SKU at our facility. Mono-dose ampoule formats require a minimum of 5,000 units due to filling line economics. Jar formats for higher-viscosity AHA creams can sometimes start at 2,000 units. These aren’t arbitrary numbers — they reflect the minimum run length where per-unit fixed costs (line setup, QC sampling, documentation) become reasonable for both sides.

Per-unit cost for a standard 10% glycolic acid toner at 150ml in a pump bottle typically ranges from $1.80–$3.20 USD depending on raw material grade, packaging spec, and batch size. Don’t hold us to that range without a proper quote — fragrance addition, specialty actives, and premium packaging can shift it significantly. What we can say is that the cost delta between a basic and a premium acid exfoliant formula is usually concentrated in two places: the active ingredient grade and the packaging material. The formula itself rarely accounts for more than 20–25% of the unit cost difference.

On development fee vs. per-unit cost: some brands want to negotiate the development fee down against a promise of high production volume. We understand the logic, but we’re cautious about this structure. Development work is discovery work — we don’t know what we’ll find until we’re in the lab. A formula that tests well at bench scale sometimes requires two or three rounds of adjustment through accelerated stability at 40°C/75% RH. Pricing the development fee as if it’s a known quantity creates problems when the chemistry doesn’t cooperate.

Evaluating Lab Samples — What to Actually Check #

When we ship you a lab sample, you’ll receive three things: the physical sample, a lab data sheet showing pH, viscosity, and appearance at time of manufacture, and a proposed evaluation checklist. Most brands focus entirely on the sensory experience — texture, skin feel, rinse-off behavior for exfoliating washes. That’s reasonable and important. But there are two other things worth checking at this stage.

Stability proxies. We’ll run a preliminary 4-week accelerated stability test at 40°C in parallel with your sensory review. By the time you’ve done your internal evaluation (typically 2–3 weeks), we’ll have early stability data. pH drift is the primary signal we watch in acid formulas. A formula that drops more than 0.3 pH units over 4 weeks at 40°C tells us the buffering system needs adjustment. Most AHA formulas we develop are buffered at pH 3.5–4.5 using sodium hydroxide or triethanolamine titration, and drift in this range is usually a sign of incomplete neutralization or preservative interaction with the acid system. This is worth understanding because a formula that looks and feels great on day one can develop off-notes and reduced efficacy by month four.

Efficacy proxies. We don’t run clinical trials on lab samples — that comes later. But we can run in-vitro corneometry (skin hydration proxy) and transepidermal water loss measurements on the formula to confirm it’s not barrier-disruptive at the intended concentration. For context: a 2019 split-face RCT (n=40, 16 weeks) published in the Journal of Cosmetic Dermatology comparing a buffered 8% glycolic acid serum against vehicle control showed 28% improvement in D-Squame corneocyte scaling scores and a statistically significant improvement in surface texture at week 8. The formula in that study was buffered to pH 3.8, which aligns with the pH range we target for efficacy-forward consumer leave-on products. That kind of benchmark matters when we’re calibrating a formula claim.

For sensory evaluation, we recommend testing the sample under your target application conditions — morning and evening for a leave-on, on wet skin for a rinse-off. Acid exfoliants feel different on damp skin than dry. If your consumer brief targets dry skin application, we need to know that because it changes how we approach the emollient balance in the formula.

From Sample Approval to First Production Batch #

This is where timeline expectations most often drift from reality. Here’s how we typically map it.

After you confirm sample approval, we initiate two things simultaneously: the full accelerated stability program (4 weeks at 40°C/75% RH, 4 weeks at 45°C, freeze-thaw cycling across 3 cycles) and the packaging compatibility study. Packaging compatibility matters more in acid formulas than in most other categories. Low-pH contents are aggressive toward certain closure materials — we’ve had a PET bottle with a PP pump closure show measurable pH shift at week 8 that wasn’t visible in the glass reference sample. The culprit was plasticizer migration from the pump tube at 40°C. This isn’t a catastrophic failure, but it’s exactly the kind of thing that gets missed if packaging isn’t tested in the actual target container.

Real-time 24-month stability runs in parallel from this point. We don’t wait for accelerated data to complete before initiating real-time — that would add three months to every project for no reason.

The manufacturing documentation package (Master Formula Record, Manufacturing SOP, QC release specifications) takes approximately 2–3 weeks to prepare after formula lock. First production batch typically follows 4–6 weeks after documentation sign-off, accounting for raw material lead times and production scheduling.

Realistic total timeline from brief submission to first production batch, assuming one round of sample revision: 14–20 weeks. If the brief is incomplete or requires reformulation after regulatory review, add 6–10 weeks. We’ve done faster. Projects with pre-approved raw material lists, clear regulatory targets, and experienced internal evaluation teams have reached production in under 12 weeks. But we plan conservatively, and we’d rather tell you 16 weeks and deliver in 14 than promise 10 and deliver in 18.

Formulation Notes for Brand Partners #

When you brief us on an acid exfoliation product, the first questions we’ll ask aren’t about the formula. They’re about your market, your consumer, and your pack story. Those three things shape every decision we make from pH selection to preservative system to packaging recommendation.

The brief mistake we see most from newer brands: requesting a specific acid concentration without specifying pH. “I want 10% glycolic acid” is not a formula brief. At pH 3.2, that’s a professional-grade peel with significant free acid activity and real regulatory exposure in most consumer markets. At pH 4.0, it’s an effective daily toner. Same concentration, completely different product. We’ll always ask this question, but if you arrive knowing the answer, we move faster.

What we need from you: target market (EU, US, China, or other — each has different regulatory thresholds), intended use (daily leave-on, weekly treatment, rinse-off), texture preference (essence, serum, cream, gel), pH tolerance from a consumer experience perspective, any exclusion list, and if you have a benchmark product, send us the INCI list or a physical sample.

Timeline: lab samples in 2–3 weeks from brief sign-off, accelerated stability running concurrently from sample approval, real-time 24-month stability initiated at the same time. Total to first production batch is typically 14–20 weeks.

Frequently Asked Questions #

We want to launch with a 10% AHA toner — what’s the minimum we need to tell you to get started?

A: Market destination first, always. A 10% AHA toner for the EU needs to sit at pH ≥ 3.5 under EU Cosmetics Regulation 1223/2009, which affects which claims you can make. After that, tell us the texture (watery, essence-weight, or slightly viscous) and whether alcohol is acceptable. Those three inputs let us set up the first bench batch without going back to you five more times.

Can we start production at 1,000 units to test the market first?

A: For most liquid acid formats, production MOQ at our facility starts at 3,000 units — that’s the break-even point for line setup and QC documentation costs. At 1,000 units, the per-unit cost roughly doubles, and some filling formats simply aren’t economical below 3,000. If you need to test at lower volume, we’d suggest looking at a pre-fill program with a simplified packaging spec, or accepting a higher per-unit cost. Either way, discuss this before the packaging spec is finalized.

Our last OEM sent us a sample that smelled fine at week two but had an off-odor at week eight. What happened?

A: Almost certainly a preservative or fragrance interaction with the acid system. Some esters used in fragrance compounds hydrolyze under sustained low-pH conditions, generating off-note aldehydes or carboxylic acids. We flag fragrance compatibility as a mandatory check in our stability protocol — every fragrance supplier we work with provides a pH stability data sheet, and we run a separate stability arm at the target pH before releasing a scented acid formula. If your previous OEM didn’t run packaging-contained stability at 40°C across 8+ weeks, that’s likely where it was missed. The PCPC Guidelines include recommendations on fragrance stability testing that are worth reviewing with your next supplier.

How long does the full development and stability process take if we’re targeting an EU launch?

A: From brief sign-off to first production batch, budget 14–20 weeks under normal conditions. EU doesn’t add time to the stability program itself, but if you’re selling through a retailer that requires a Cosmetic Product Safety Report, factor in 4–6 additional weeks for the responsible person review after stability data is complete. Don’t leave the CPSR to the last month — it’s the most common bottleneck we see on EU-targeted projects, and it has nothing to do with the formula quality.

Should we specify the exact pH on our packaging or brief?

A: Careful here. Specifying a pH on pack in certain markets triggers closer regulatory scrutiny — in China under NMPA Cosmetic Regulation, pH claims can affect product classification and registration requirements. Our recommendation is to align internally on a target pH range and hold it tightly in your QC specification, but avoid making pH a marketing claim unless you have a specific reason to. The claim that matters to the consumer is the outcome (smoother texture, reduced congestion), not the number. We’ll help you build the substantiation for the outcome claim — that’s a more defensible position than competing on pH digits.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.